IPP Bureau
71% of Indians targeted by health scams amid rise of AI-generated misinformation: McAfee study
By IPP Bureau - June 23, 2026
Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
Pfizer lung cancer drug misses key survival goal in Phase 3 trial
By IPP Bureau - June 23, 2026
The company said the safety profile remained consistent with earlier studies and was considered manageable
Girls with ADHD from deprived backgrounds face sharply higher risk of long-term health conditions: Study
By IPP Bureau - June 23, 2026
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
AbbVie to acquire Apogee in $10.9 billion immunology power play
By IPP Bureau - June 23, 2026
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Suven Life Sciences to spotlight CNS pipeline & strike partnering deals at BIO-2026 San Diego
By IPP Bureau - June 23, 2026
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Pfizer CFO Dave Denton to exit
By IPP Bureau - June 23, 2026
Pharma powerhouse names Cecile Guegan interim finance chief
Teva closes $700M Emalex acquisition
By IPP Bureau - June 23, 2026
Bolstering neuroscience push with late-stage Tourette therapy
FDA fast-tracks Roche cancer drug filing after landmark trial shows 50% recurrence reduction
By IPP Bureau - June 23, 2026
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
AbbVie unveils 9-Yr CLL data showing lasting survival benefit for Venetoclax-based therapy
By IPP Bureau - June 23, 2026
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Biopharma funding rebounds in 2026, but capital flows to lower-risk assets
By IPP Bureau - June 22, 2026
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla
By IPP Bureau - June 22, 2026
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
MICK Digital empanelled as AMTZ authorized channel partner
By IPP Bureau - June 22, 2026
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
BPL Medical honours strategic partners with Pinnacle Awards 2026
By IPP Bureau - June 22, 2026
The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024
Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition
By IPP Bureau - June 22, 2026
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram
By IPP Bureau - June 22, 2026
New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month
